Clinical Guideline Highlights for the Hospitalist: Therapeutic Monitoring of Vancomycin.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33231544.
- Also identified by DOI 10.12788/jhm.3507 and PMC identifier 8034673.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists RELEASE DATE: Online: March 19, 2020 PRIOR VERSION: 2009 DEVELOPERS: American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) FUNDING SOURCE: ASHP, IDSA, PIDS, SIDP TARGET POPULATION: Adults, children, and neonates treated for documented or presumed methicillin-resistant Staphylococcus aureus infection.
Medical subject headings
- Communicable Diseases
- Hospitalists
- Methicillin-Resistant Staphylococcus aureus
- Staphylococcal Infections